Additionally, men in the radiotherapy group faced three times the risk of a bladder cancer diagnosis. ‘Men need clear data on ...

Men who undergo prostate cancer treatment face a greatly increased risk of life-altering, long-term complications, a new ...

A recent study reveals that extended lymphadenectomy offers no survival advantage over standard lymphadenectomy for patients ...

Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and ...

The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...

Patients with muscle-invasive bladder cancer who underwent whole pelvis radiation showed improved cancer-specific survival and overall survival.

This project aims to bring cutting-edge molecular diagnostics to Saudi Arabia using a 23-gene panel to detect key genetic ...

Balversa (erdafitinib) marks the first and only bladder cancer therapy to target FGFR3 alterations, with a demonstrated increase in overall survival from 7.8 months to 12.1 months. On Nov. 6, 2024, ...

Medically reviewed by Andrea L. Braden, MD A bladder ultrasound is a noninvasive imaging technique used to check for ...

Researchers conducted a cohort study to try to characterize long-term treatment-related adverse effects and complications in ...

Lower abdominal visceral fat area (VFA), older age, and prolonged surgery are independent risk factors for developing ...